Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses
Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses
批准号:
8946258
负责人:
PETER LEON COLLINS
金额:
$107.29万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AffectAgeAmino AcidsAntiviral TherapyAttenuatedAttenuated Live Virus VaccineAutologousBasic ScienceCD209 geneCD4 Positive T LymphocytesCell MaturationCercopithecus pygerythrusChildhoodCloningCodeCodon NucleotidesComplementary DNAConfocal MicroscopyDendritic CellsDevelopmentElderlyEndocytosisExhibitsFamilyGene DeletionGenesGeneticGenetic CodeGenetic VariationGenomeGeometryGlycoproteinsGoalsGrowthHandHumanHuman MetapneumovirusHuman poliovirusHuman respiratory syncytial virusImmuneImmune responseImmunityImmunocompromised HostIn VitroIndividualLaboratory StudyLeftLifeMediatingMessenger RNAMethodsMinorMolecularMolecular BiologyMolecular GeneticsMorbidity - disease rateMusNatureNonstructural ProteinNucleoproteinsNucleotidesOpen Reading FramesPTPN11 geneParamyxovirusPathway interactionsPhenotypePhosphoproteinsPneumovirusPoliovirusesPolymerasePopulationProteinsRNARNA VirusesReagentRecombinant DNARefractoryReportingRespiratory Syncytial Virus VaccinesRespiratory Tract DiseasesRespiratory syncytial virusRespiratory syncytial virus RSV proteinsRibosomesRoleSiteSystemT VirusT-Cell ProliferationT-LymphocyteTemperatureTimeTransfer RNATranslationsVaccine DesignVaccinesViralViral ProteinsVirusVirus Replicationattenuationbasedesigngenome sequencingglycoprotein Ghuman diseaseimmunogenicityimmunological synapseimprovedinfluenzavirusinterestmemory CD4 T lymphocytemonocytemortalitymultiple myeloma M Proteinmutantnovel vaccinespathogenpolypeptidepositional cloningpreclinical studyprotein foldingresearch and developmentresearch clinical testinguptakevaccine candidatevaccine development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
RSV and HMPV are cytoplasmic enveloped RNA viruses of the paramyxovirus family. Their genomes are single strands of negative-sense RNA of 15.2 kb (RSV) or 13.3 kb (HMPV) that encode 10 mRNAs and 11 unique proteins (RSV) or 8 mRNAs and 9 unique proteins (HMPV). Each virus encodes a nucleoprotein N, phosphoprotein P, matrix protein M, small hydrophobic protein SH, major glycoprotein G, fusion glycoprotein F, polymerase factors M2-1 and M2-2, and the polymerase protein L. In addition, RSV encodes two nonstructural proteins NS1 and NS2.
We evaluated the strategy of codon-pair deoptimization (CPD) as a means of developing genetically and phenotypically stable attenuated RSV strains. It is well known that there is a bias in codon-pair usage in nature. Specifically, any given pair of amino acids in a polypeptide chain has the possibility to be encoded by a variety of different combinations of synonymous codons due to the degeneracy of the genetic code, but the observed usage of codon-pairs typically is biased to favor a subset of the possible combinations. One factor in this bias is thought to be translational efficiency and accuracy, because certain combinations of tRNA pairs are favored at the A and P sites in the ribosome due to tRNA geometry and other factors. CPD involves the deliberate introduction of under-represented synonymous codon-pairs into numerous sites in protein-coding sequence to achieve sub-optimal expression. These substitutions only involve the ORFS, and thus non-protein-coding genome regions are not affected. Also, CPD involves only synonymous codon substitutions, and thus amino acid coding is unaffected. In addition, CPD applied to one or several genes typically involves hundreds or thousands of nucleotide changes, and thus should be highly refractory to de-attenuation. Recently, CPD was applied to poliovirus and influenza virus and was shown to result in attenuated strains.
We designed the following set of four CPD RSV genomes in which the indicated ORFs were recoded: (i) Min A; NS1, NS2, N, P, M, and SH (i.e., the left-hand third of the genome); (ii) Min B; G and F (located in the middle of the genome); (iii) Min L; L (located at the right-hand end of the genome); and (iv) Min FLC; all ORFs except M2-1 and M2-2. The recoded genome regions were synthesized commercially and the four CPD viruses were constructed and recovered by reverse genetics. All of the CPD viruses were temperature-sensitive (level of sensitivity: Min FLC>Min L>Min B>Min A) for replication in vitro. We speculate that CDP may slow down the rate of translation sufficiently to create protein-folding problems that are exacerbated by increased temperature. All of the CPD mutants grew less efficiently in vitro than wild type (wt) RSV, even at the permissive temperature of 32C (growth efficiency: wt>Min L>Min A>Min FLC>Min B). Thus, CPD of G and F ORFs provided the greatest effect. The CPD viruses exhibited a range of restriction in mice and African Green Monkeys (AGM) and induced immunity against wt RSV. This study identified new vaccine candidates for RSV and showed that CPD of a nonsegmented negative-strand RNA virus can rapidly generate vaccine candidates with a range of attenuation phenotypes.
We used gene-deletion HMPV strains to evaluate the role of the attachment G and small hydrophobic SH glycoproteins on HMPV uptake by primary human monocyte-derived dendritic cells (MDDC) in vitro, and on subsequent MDDC maturation and activation of autologous T cells. Deletion of G and SH (delSHG) conferred increased infectivity but had little effect on MDDC maturation. However, MDDC stimulated with ΔSHG induced increased proliferation of autologous Th1-polarized CD4+ T cells. This effect was independent of virus replication. Increased T cell proliferation was strictly dependent on contact between virus-stimulated MDDC and CD4+ T cells. Confocal microscopy revealed that deletion of SH and G was associated with an increased number of immunological synapses between memory CD4+ T cells and virus-stimulated MDDC. Uptake of HMPV by MDDC was found to be primarily by macropinocytosis. Uptake of wild-type (WT) virus was reduced compared to ∆SHG, indicative of inhibition by the SH and G glycoproteins. In addition, DC-SIGN-mediated endocytosis provided a minor alternative pathway that depended on SH and/or G and thus operated only for WT. Altogether our results show that SH and G glycoproteins reduce the ability of HMPV to be internalized by MDDC, resulting in a reduced ability of the HMPV-stimulated MDDC to activate CD4+ T cells. This study describes a previously unknown mechanism of virus immune evasion. This is of interest because reinfection by HMPV is common throughout life without need for significant antigenic change, suggesting that protective immune response to HMPV is incomplete and short-lived. The present study provides a mechanism that might contribute to suppressing host immunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FUNCTIONS OF THE PROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
-
批准号:6098950
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
REPLICATION,VIRULENCE & IMMUNOGENICITY IN RECOMBINANT RESPIRATORY SYNCYTIAL V
-
批准号:6098927
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
STRUCTURAL ANALYSIS OF THE GENOME OF RESPIRATORY SYNCYTIAL VIRUS
-
批准号:6288840
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
FUNCTIONS OF THE PROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
-
批准号:6288863
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
FUNCTIONS OF THE PROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
-
批准号:6431577
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Metapneumovirus Biology and Vaccine Development
-
批准号:6985263
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Metapneumovirus Biology and Vaccine Development
-
批准号:7192840
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
-
批准号:7964502
-
项目类别:
-
资助金额:$142.51万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
-
批准号:9566628
-
项目类别:
-
资助金额:$231.32万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses
-
批准号:8745290
-
项目类别:
-
资助金额:$191.68万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
-
批准号:9161440
-
项目类别:
-
资助金额:$152.01万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
-
批准号:8336177
-
项目类别:
-
资助金额:$166.16万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Metapneumovirus Biology and Vaccine Development
-
批准号:7732445
-
项目类别:
-
资助金额:$100.86万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses
-
批准号:10014018
-
项目类别:
-
资助金额:$154.41万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
-
批准号:8156824
-
项目类别:
-
资助金额:$149.67万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
REPLICATION,VIRULENCE & IMMUNOGENICITY IN RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS
-
批准号:6288842
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
In Vitro Models of Paramyxovirus Infection
-
批准号:6985695
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
-
批准号:8555881
-
项目类别:
-
资助金额:$43.36万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Metapneumovirus Biology and Vaccine Development
-
批准号:7964244
-
项目类别:
-
资助金额:$54.57万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
Human Respiratory Syncytial Virus Biology And Vaccine Development
-
批准号:8336046
-
项目类别:
-
资助金额:$127.27万
-
财政年份:--
-
负责人:PETER LEON COLLINS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: